Tiziana Life Sciences completes Phase 2a INFORM-MS last patient visit for intranasal foralumab in na-SPMS
TLSA•Phase 2a INFORM-MS trial reaches last patient visit
- Tiziana reported the last patient completed the final visit in its Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.
- Topline 12-week treatment results have not been presented yet; release is scheduled for October following a database lock this week.
- The study is designed to show whether the therapy can safely reduce disease-related brain immune activity, with signals on disability and fatigue.
- Participants can enter a six-month open-label extension, supporting longer-term safety and potential durability readouts.
- Management pointed to expanded-access experience suggesting patients generally held steady or improved, setting expectations into the October data event.
